DMN:FRA
Diamyd Medical AB
0,064 €
arrow_upward
+1,92%(+0,0012) 1D
20-ноя., 08:04:51 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
136,63 млн
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
136,63 млн
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
The Motley Fool
·
52 мүнөт мурун
Bitcoin Is 35% Below Its 52-Week High While the S&P 500 Is Up. Here’s What That Says About the Digital Gold Thesis.
MarketWatch
·
29 мүнөт мурун
Here’s what happened next after previous times the S&P 500 losing streak reached six sessions
Benzinga
·
27 мүнөт мурун
Stock Market Today: Dow Jones, S&P 500 Futures Fall as Trump Weighs Iran Decision— INTU, ROST, KEYS in Focus
MarketForces Africa
·
2 саат мурун
S&P 500, Nasdaq, Dow Jones Dip Amidst Anthropic IPO Debut
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB